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Ornithine carbamoyltransferase (OTC) is a key enzyme in the
urea cycle to detoxify ammonium produced from amino acid
catabolism. OTC deficiency is an X-linked genetic disorder
ranging from fatal in newborns to hyperammonemia and ano-
rexia in adults. Through affinity purification of acetylated pep-
tides and mass spectrometry, we identified that OTC is acety-
lated on lysine residues, including Lys88, which is also mutated
in OTC-deficient patients. OTC acetylation was confirmed to
occur under physiological conditions. Biochemical character-
izations revealed thatOTCLys88 acetylation decreases the affin-
ity for carbamoyl phosphate, one of the twoOTCsubstrates, and
the maximum velocity, whereas the Km for ornithine, the other
OTC substrate, is not affected. Furthermore, Lys88 acetylation is
regulated by both extracellular glucose and amino acid avail-
ability, indicating thatOTCactivitymay be regulated by cellular
metabolic status. Our results provide an example of the novel
mechanism of regulating metabolic enzyme activity through
protein acetylation.
Ornithine carbamoyltransferase (OTC)3 is anX-linkedmito-
chondrial enzymemainly expressed in hepatocytes and entero-
cytes.OTC is synthesized as a precursor, and themitochondrial
import is accompanied by removal of the N-terminal signal
peptide to produce a 36-kDa mature enzyme. As a key urea
cycle enzyme, OTC catalyzes the reaction that converts orni-
thine and carbamoyl phosphate into citrulline. Ornithine is the
deamination product of arginine, whereas carbamoyl phos-
phate is the condensation product of ammonium generated by
amino acid deamination and carbon dioxide. Thus, OTC is of
crucial importance for cellular ammonium secretion (as a form
of urea) and amino acid catabolism (1).
Because there is no alternative way of urea synthesis, block-
ade in the urea cycle results in devastating health consequences.
OTCmutation is a relative common genetic disorder in human.
A deficiency of OTC usually results in central nervous system
dysfunction, whichmay cause irreversible brain damage ormay
be fatal in newborn infants (2). OTC deficiency in adults has
milder symptoms but still causes health problems such as
hyperammonemia (3, 4) and anorexia (5). Because the gene is
on theX chromosome,OTCdeficiency ismuchmore prevalent
in males. There are 340 OTCmutations identified so far with
clinical symptoms (6). No obvious hot spot for OTCmutations
has been found. All null mutations are associated with severe
neonatal phenotypes, and none survived beyond 5 days of life
without treatment. Most disease-associated OTC mutants are
missense mutations (7). These observations suggest an indis-
pensable role for OTC activity in human physiology.
Addition of acetyl moiety to the -amino group of a lysine
residue is a common mechanism of post-translational modifi-
cation. Protein acetylation regulates various aspects of protein
functions, such as regulating protein-protein interaction (8).
The role of acetylation in regulating nuclear proteins and tran-
scriptional factors has been well established after more than a
decade of intense research. Histone acetylation affects chroma-
tin structure and gene expression (9–11); tumor suppressor
protein p53 can be acetylated at multiple sites, and different
acetylation modifications have distinct effects on p53 function
and physiological impact on the cell (12, 13). The regulatory
role of acetylation in enzyme activity was first reported in
acetyl-CoA synthetase (14), in which the active site lysine resi-
due in the Salmonella enterica enzyme is acetylated, and there-
fore, acetylation inhibits acetyl-CoA synthetase activity.
Acetyl-CoA synthetase in other species has also been reported
to be regulated by acetylation of the active site lysine residue
(15, 16), indicating a conserved regulatorymechanismby acety-
lation for this enzyme.
We performed a proteomic analysis of protein acetylation in
human liver. Our studies have identified that lysine 88 in OTC
is acetylated. Interestingly, the OTC three-dimensional struc-
ture (17–19) shows that Lys88 is not only localized near the
carbamoyl phosphate-binding residues (residues 90–93) but
that it is also involved in the formation of a complex hydrogen-
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bonded network that directly par-
ticipates in substrate binding, indi-
cating a critical role of Lys88 in
catalysis. Furthermore, mutation of
Lys88 is found in human OTC-defi-
cient patients (20). These two lines
of evidence suggest that acetylation
on Lys88 may play a key role in the
regulation of OTC activity. In this
study, we have characterized the
OTC acetylation and found that
Lys88 acetylation inhibits OTC
activity. Furthermore, the Lys88
acetylation is affected by cellular
metabolic status, indicating a possi-
ble role of acetylation in physiologi-
cal regulation.
EXPERIMENTAL PROCEDURES
Cell Culture and Transfection—
HEK293T and Chang liver cells
were cultured in Dulbecco’s modi-
fied Eagle’s medium (Invitrogen)
supplemented with 10% fetal calf
serum (HyClone), 100 units/ml
penicillin, and streptomycin (In-
vitrogen). Cell transfection was per-
formed using Lipofectamine 2000




antibodies were generated using
chemically modified acetylated
chicken ovalbumin as antigen. Poly-
clonal antibodies against acetylated
OTC Lys88 were generated in rab-




ments were carried out by adding
trichostatin A (TSA; 0.5 M) and/or
nicotinamide (NAM; 5 mM) into
culture medium 16 h before har-
vesting; both concentrations are
final concentrations in the culture
medium.
Glucose/Amino Acid Treatment—
Cells or transfected cells were kept
in Dulbecco’s modified Eagle’s
medium for 24 h before treatment.
Cells were washed twice with phos-
phate-buffered saline and contin-
ued culture in Dulbecco’s modified
Eagle’s medium (without glucose
but with essential amino acids;
Sigma, D5030) with the desired sup-
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plementation of glucose or amino acids. Amino acid concentra-
tions were the total concentrations of equimolar glutamate and
aspartate. Cells were harvested after 12 h of treatment.
Immunoprecipitation—Cells were lysed with lysis buffer (50
mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM EDTA, 1% Nonidet
P-40, 50 mM NaF, 1.5 mM Na3VO4, protease inhibitor mixture
(Roche), 1 mM dithiothreitol, and 1 mM phenylmethylsulfonyl
fluoride). For anti-FLAG immunoprecipitation (IP), 500 l of
cell lysate was incubated with anti-FLAGM2-agarose for 4 h at
4 °C; for OTC antibody IP, lysate was incubated with anti-OTC
antibody (Aviva Systems Biology; 1:500) overnight and then
protein A/G beads were added, and incubation was continued
for another 2 h. Beadswerewashed three timeswith lysis buffer,
and the FLAG-tagged proteins were eluted by FLAG peptides
(Gilson Biochemical).
His-tagged Protein Expression and Purification—His-tagged
wild-type OTC, K88Q, and K88R proteins were expressed in
Escherichia coli BL21(DE3). After reaching a middle exponen-
tial growing stage, 0.2 mM isopropyl 1-thio--D-galactopyran-
oside was added to the bacterial culture to induce protein over-
expression. Induction was carried out at 20 °C for 4 h.
Expressed proteins were purifiedwith nickel beads (GEHealth-
care) as recommended by the manufacturer. Purified proteins
were stored at 80 °C in 10% glycerol.
OTC Assay—The OTC enzyme assay was adapted from a
published method (21). Briefly, 5 l of FLAG peptide-eluted
ectopic OTC-FLAG solution or 10 l of OTC antibody-immu-
noprecipitated beads was added to a solution containing orni-
thine and triethanolamine to a final volume of 675 l. OTC
reactions were started by adding 75 l of 150 mM carbamoyl
phosphate. Final concentrations in assay of each reagent were 5
mMornithine, 15mM carbamoyl phosphate, and 270mM trieth-
anolamine, pH 7.7. After 30 min of incubation at 37 °C, reac-
tionswere stopped by adding 375l of phosphoric acid/sulfuric
acid (3:1, v/v). Citrulline production was determined by adding
47 l of 3% 2,3-butanedionemonoxime, boiling in the dark for
15 min, and reading absorbance at 490 nm.
RESULTS
OTC Is Acetylated at Lys88—Most reported acetylation stud-
ies are with nuclear proteins, whereas few cytoplasmic protein
acetylation studies have been documented. To investigate non-
nuclear protein acetylation, human liver tissuewas fractionated
into nuclear, cytosolic, mitochondrial, and membrane frac-
tions. The subcellular fractions were digested with trypsin, and
acetylated peptides were purified by anti-acetyllysine antibody
followed by tandem liquid chromatography-tandemmass spec-
trometry analysis. Among many acetylated peptides identified,
the peptide SLGMIFEK*Rwas identified in bothmitochondrial
andmembrane fractions from liver samples (Fig. 1A). A Sequest
Technologies search indicated that this peptide matches
humanOTCprotein and that the acetylated lysine is Lys88. This
acetylation peptide was identified in multiple independent
experiments. Interestingly, an independent proteomic survey
by Kim et al. (22) also reported that the same peptide is acety-
lated in mouse OTC. Lys88 in OTC is highly conserved in dif-
ferent species from Saccharomyces cerevisiae to human (Fig.
1B), indicating a critical role in OTC function.
We are aware of the possibility that lysine acetylation may
come from the in vitro manipulation during sample prepara-
tion. For example, formic acid used in solubilizing peptides dur-
ing mass spectrometry assay could be contaminated by trace
amounts of acetate anhydrate, and this contamination could
cause acetylation of peptides during sample preparation. TSA is
a potent inhibitor toward both class I and II deacetylase,
whereasNAMcan inhibit class III deacetylase (23–25). To con-
firm that OTC Lys88 is acetylated in vivo, human OTC gene
with a FLAG tag at theC terminuswas cloned into pcDNA3and
expressed in HEK293T cells, and the transfected cells were
treated with deacetylase inhibitors. p53, a well known acety-
lated protein, was included as a positive control. OTC and p53
proteins were immunoprecipitated from transfected cells fol-
lowed by Western blotting for lysine acetylation. Interestingly,
like p53, TSA and NAM treatment also significantly enhanced
OTC acetylation (Fig. 1C). These results confirmed thatOTC is
acetylated in vivo.
To further examine whether endogenous OTC is acetylated,
Chang liver cells were treated with or without TSA plus NAM.
Endogenous OTC protein was precipitated with an anti-OTC
antibody, and the acetylation level of OTC was probed by anti-
acetyllysine antibody. We found that the endogenous OTC
acetylation level was significantly increased by treatment with
TSA and NAM (Fig. 1D). These results indicate that OTC is
acetylated under physiological conditions, and the acetylation
of OTC is negatively regulated by deacetylases.
Our mass spectrometry data showed that OTC is possibly
acetylated on two additional lysine residues, Lys46 and Lys231. A
rise in total acetylation detected by anti-acetyllysine antibody is
not sufficient to conclude that OTC Lys88 is acetylated. To
directly detect OTC Lys88 acetylation, we raised antibody
against an acetylated Lys88 OTC peptide. As shown in Fig. 1E,
the site-specific antibody recognized the overexpressed wild-
type OTC Lys88 acetylation, and the acetylation level of OTC
Lys88 increased upon TSA plus NAM treatment. The antibody,
however, could not recognize the OTC K88Q mutant, indicat-
ing that the antibody is specific for acetylated Lys88 in OTC.
FIGURE 1. OTC is acetylated at Lys88. A, shown is a tandem mass spectrum of the acetylated OTC lysine 88-containing peptide SLGMIFEK*R. B, the acetylated
Lys88 in OTC is conserved. The sequences around OTC Lys88 from different species were aligned. Conserved lysine residues corresponding to human OTC Lys88
are boxed. C, transfected OTC is acetylated. HEK293T cells were transfected with pcDNA3 vector, pcDNA3-hOTC-FLAG, and pcDNA3-FLAG-p53 followed by
deacetylase inhibitor treatment. Cell lysate was immunoprecipitated with FLAG beads. The precipitated OTC-FLAG was detected by anti-FLAG antibody and
anti-acetyllysine antibody (-AcK) as indicated. NAM and TSA denote treatment with nicotinamide and triochostatin A, respectively. D, endogenous OTC is
acetylated. Chang liver cells were treated with deacetylase inhibitors. Endogenous OTC protein was immunoprecipitated with anti-OTC antibody. The acety-
lation level of endogenous OTC was probed by anti-acetyllysine antibody. E, OTC is acetylated on Lys88. HEK293T cells were co-transfected by
pcDNA3-hOTC-FLAG and pcDNA3-hOTCK88Q-FLAG. OTC proteins were precipitated by FLAG beads. OTC Lys88 acetylation levels were detected by an anti-
body raised against OTC Lys88 peptide.
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The above data demonstrate that Lys88 in OTC is indeed
acetylated.
Inhibition of Deacetylase Activity Reduces OTCActivity—Ly-
sine 88 has been implicated to be important for OTC catalysis
(26). Therefore, acetylation of Lys88 will likely affect its enzy-
matic activity. We hypothesize that if OTC Lys88 acetylation
regulates its enzyme activity, inhibiting deacetylases could
increase the acetylation level of Lys88 and in turn, affect OTC
activity. Both endogenous and overexpressed OTC activities
were examined to test this hypothesis. We first examined OTC
activity regulation by deacetylase inhibitors in transfected
HEK293 cells. OTC was transfected into HEK293T cells, and
the cells were treated with NAM or TSA. OTC protein was
immunopurified, and the activity was measured. We observed
that the immunoprecipitated OTC activity was inhibited in
cells treated with TSA and NAM (Fig. 2A). An inverse correla-
tion between OTC acetylation and activity strongly indicates
that OTC activity is negatively regulated by acetylation. Fur-
thermore, Chang liver cells were cultured in the absence or
presence of deacetylase inhibitors, TSA andNAM.Endogenous
OTC was immunoprecipitated by OTC antibody-conjugated
protein A/G beads, and OTC activity was measured on beads.
We found that eitherTSAorNAMtreatment decreased endog-
enous OTC activity (Fig. 2B). The reduction of OTC activity by
TSA and NAM indicates that endogenous OTC activity is
inhibited by acetylation.
Lys88 Acetylation Inhibits OTCActivity—The human disease
associated with the K88N mutation causes OTC deficiency,
although this mutant OTC has residual activity (27). This is
consistent with our finding that inhibition of deacetylases
decreases OTC activity. To test the importance of Lys88 acety-
lation in OTC regulation, we generated the K88R and K88Q
mutants. The K88R mutation retains a positive charge and is
thus considered as a conserved substitution. K88Q, on the
other hand, abolishes the positive charge, and therefore, may
mimic the effect of acetylation. Bothmutants were expressed in
HEK293T cells, and OTC activities were determined from
immunoprecipitated protein. The K88R mutant retains sub-
stantial enzymatic activity, although it is reduced (Fig. 3A). In
contrast, the K88Q mutant is essentially inactive, with 1% of
the wild-type OTC activity. These results indicate that a posi-
tive charge at position 88 is critical for OTC catalytic activity.
Substitution of Lys88 by a glutamine effectively abolishes OTC
activity, consistent with our notion that acetylation inhibits
OTC activity. We also mutated Lys46 and Lys231, the other two
acetylated lysine residues identified in our mass spectrometry
data, to glutamines and found that mutation of these two lysine
residues had little effect onOTC activity. These results indicate
that acetylation of Lys46 and Lys231 is not directly involved in
enzyme activity regulation.
It is thus of interest to determine whether Lys88 is the pri-
mary regulatory acetylation site for OTC activity. We took
advantage of the fact that the K88R mutant retains substantial
activity. We compared the enzymatic activity of the wild type
and the K88R mutant in response to deacetylase inhibitors. As
expected, treatment with TSA andNAMdecreasedOTC enzy-
matic activity with a concomitant increase in overall OTC
acetylation and Lys88 acetylation (Fig. 3B). In contrast, TSA and
NAM failed to inhibit the OTC K88R mutant, although overall
acetylationwas still increased by the deacetylase inhibitors (Fig.
3B). The increase in OTC K88R acetylation is likely due to
acetylation of other lysine residues in OTC. Our data strongly
indicate that acetylation of Lys88 is responsible forOTC activity
inhibition in response to deacetylase inhibitors.
The three-dimensional structure of OTC suggests that a
modification at Lys88 may affect OTC substrate binding and
thus affect OTC activity. To further investigate the mechanism
by which Lys88 acetylation reduces OTC activity, we expressed
FIGURE 2. Inhibition of deacetylase reduces OTC activity. A, deacety-
lase inhibitors decrease transfected OTC activity. HEK293T cells were
transfected with pcDNA3-hOTC-FLAG and treated with deacetylase inhib-
itors as indicated. OTC proteins were immunoprecipitated with FLAG
beads and were eluted by 100 l of FLAG peptide. OTC assay was carried
out, and specific activity was normalized by OTC protein levels deter-
mined by Western blotting. Shown are mean  S.D. of duplicate assays.
The overall acetylation level and Lys88 acetylation level were assayed by
anti-acetyllysine antibody or anti-acetyllysine-88 antibody. B, NAM and
TSA inhibit endogenous OTC activity. Chang liver cells were treated with
deacetylase inhibitors. OTC protein was immunoprecipitated with anti-
OTC antibody and measure the OTC activity in protein A/G beads. Anti-
hemagglutinin (HA) antibody was used as an IP control. Bars and error bars
represent mean  S.D. of triplicate assays. Specific OTC activities were
normalized by the OTC protein level.
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and purified wild-type OTC and the
K88R and K88Q mutants from
E. coli. Kinetic studies of the puri-
fied OTC show that substitution of
Lys88 by either arginine or gluta-
mine does not significantly alter the
Km for ornithine, suggesting that
Lys88 is not directly involved in
ornithine binding (Table 1). In con-
trast, the K88Q mutant increased
the Km of carbamoyl phosphate by
10-fold compared with the wild-
type protein, whereas the K88R
mutant did not significantly
increase the Km. These data suggest
that the positive charge residue at
position 88 is important for carbam-
oyl phosphate binding. The above
observations indicate that acetyla-
tion of Lys88 in OTC may decrease
its substrate binding toward car-
bamoyl phosphate by neutralizing
the positive charge of Lys88. Given
that the physiological concentration
of carbamoyl phosphate is 0.1 mM
in liver cells (28, 29), the acetylated
OTCwould have very low activity. It
is worth noting that the K88Q
mutant not only altered OTC sub-
strate binding but also dramatically
decreased the maximum velocity.
TheOTCK88Rmutant also shows a
decreased Vmax, although it is much
less severe than the K88Q mutant.
Our results support a model that
OTC activity is negatively regulated
by Lys88 acetylation.
Lys88 Acetylation Is Influenced
by Glucose and Amino Acid
Availability—OTC functions in
urea cycle and amino acid catabo-
lism, which may be affected by the
availability of cellular fuel. We
therefore tested the effect of glucose
and amino acids on OTC acetyla-
tion. We found that lowering the
glucose levels led to a decrease in
Lys88 acetylation, as determined by
the Lys88 acetylation-specific anti-
body (Fig. 4A). At the same time,
OTC activity was increased by low-
ering glucose levels in cell culture
medium (Fig. 4A), consistent with
an inhibitory effect of Lys88 acetyla-
tion on OTC activity. This result
suggests that an increase in Lys88
acetylation may contribute to OTC
inhibition by high glucose. We also
FIGURE 3. Acetylation of Lys88 inhibits OTC activity. A, Lys88 is important for full OTC activity. The
wild-type OTC and K88R and K88Q mutants were expressed in HEK293T cells. Proteins were purified by IP,
and OTC activity assays were determined. Relative specific OTC activities were normalized by protein level.
Wild-type OTC activity was arbitrarily set as 100%. -Hemagglutinin (HA) antibody was used as an IP
control. Bars and error bars represent mean  S.D. of triplicate assays. B, Lys88 is required for NAM and TSA
to repress OTC activity. OTC and the K88R mutant proteins were overexpressed in HEK293T cells followed
by deacetylase inhibitor treatment. Proteins were purified by IP, and the total acetylation level, Lys88
acetylation level, and OTC activities were determined, respectively. Relative specific OTC activities were
normalized by protein level. -Hemagglutinin antibody was used as an IP control. Bars and error bars
represent mean  S.D. of triplicate assays.
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tested the effect of amino acids (glutamate and aspartate) on
OTC acetylation. Surprisingly, higher amino acid concentra-
tions also increasedOTC Lys88 acetylation and decreasedOTC
activity (Fig. 4B). These observations established a direct link
between OTC Lys88 acetylation and the availability of extracel-
lular fuels/nutrients, consistent with the notion that OTC
acetylation plays a role in cellular metabolic regulation.
DISCUSSION
The regulatory role of protein acetylation in gene expression
has been well established (30). Interestingly, many metabolic
enzymes are also found to be acetylated by proteomic survey in
multiple species, ranging from bacteria (31) to human.4 How-
ever, the functional significance of acetylation in metabolic
enzymes is largely unknown. Besides the mass spectrometry
data of identifying acetylation, few metabolic enzymes have
been functionally characterized regarding the role of acetyla-
tion in physiological regulation. One example is the acetyl-CoA
synthetase, which is inhibited by lysine acetylation (15). This
report on OTC provides another example that acetylation
inhibits the urea cycle enzyme OTC activity by modifying a
critical lysine residue in substrate binding and catalysis. More-
over, our data indicate that OTC acetylation is regulated by
cellular nutrient signals, as OTC acetylation is enhanced by
high glucose or amino acids.
Lysine 88 is the key acetylation site responsible forOTC inac-
tivation. Lys88 locates in a position important for substrate
binding/catalysis. Consistently, K88Q has amuchweaker affin-
ity toward the substrate carbamoyl phosphate and is almost
completely inactive (less than 1% of the wild-type activity).
These observations confirm that acetylation may inhibit OTC
activity. On the other hand, the K88R mutant had no effect on
substrate binding and still retained20% catalytic activity. The
moderate reduction in OTC activity of the K88R mutation
could be due to the size change in the side chain upon arginine
substitution, although the arginine retains the positive charge.
On the basis of the mutation analysis and acetylation study, we
conclude that acetylation of Lys88 inhibits OTC catalytic activ-
ity. It is worth noting that mutation of Lys88 has been found in
human OTC deficiency disease, further supporting an impor-
tant role of Lys88 acetylation in physiological regulation.
Cells utilize glucose as the preferred energy source. When
glucose is not abundant, cells shift to alternative energy sources,
such as fatty acids and amino acids.Utilization of amino acids as
an energy source brings two problems to the cell. First, amino
acids are important building blocks for proteins, and biosynthe-
sis of amino acids is energy-expensive; thus, amino acids would
not be the preferred energy source. Second, amino acid catab-
olism produces ammonium, which is toxic to the body. There-
fore, cellsmust adapt tometabolic pathways to get rid of ammo-
nium. The urea cycle is a key pathway for ammonium
metabolism. For these reasons, urea cycle enzyme activities
need to adapt to different extracellular fuel availability. We
found that when glucose concentration is high, OTC Lys88
acetylation is increased, and the OTC activity is turned down
(Fig. 4A). Therefore, the urea cycle activity is repressed in the
4 W. Yu, Y. Lin, J. Yao, W. Huang, Q. Lei, Y. Xiong, S. Zhao, and K.-L. Guan,
unpublished data.
FIGURE 4. Lys88 acetylation is influenced by glucose and amino acid avail-
ability. A, glucose increases OTC acetylation and decreases activity. OTC-
FLAG proteins were overexpressed in HEK293T cells cultured under different
glucose concentrations as indicated. Proteins were purified by IP. OTC activ-
ity, OTC acetylation, and Lys88 acetylation were each carried out for purified
proteins. Shown are the mean  S.D. values of triplicate assays for relative
OTC activities. Enzyme activity at 0 mM amino acid was arbitrarily set as 100%.
All specific activities were normalized by protein levels. B, amino acids
increase OTC Lys88 acetylation and decrease activity. OTC-FLAG proteins
were overexpressed in HEK293T cells cultured under different amino acid
concentrations as indicated. Proteins were purified by IP. OTC activity, OTC
acetylation, and Lys88 acetylation were each carried out for purified proteins.
Mean  S.D. values of triplicate assays for relative OTC activities were pre-
sented. Enzyme activity at 25 mM glucose was arbitrarily set as 100%. All
specific activities were normalized by protein levels.
TABLE 1






Wild type OTC 90.9  3.5 0.13  0.01 0.36  0.13
OTC K88Q 0.6  0.1 1.24  0.20 0.55  0.08
OTC K88R 16.7  1.9 0.15  0.03 0.42  0.09
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abundance of glucose. This makes physiological sense because
cells do not need to catabolize amino acids for energy in the
presence of glucose. When glucose concentration is decreased,
the increase of OTC activity is possibly due to Lys88 deacetyla-
tion. This can be explained by the fact that when cells experi-
ence glucose shortage, they need to find an alternative energy
source such as amino acids. The detoxification of ammonium
generated from amino acid catabolism requires high urea cycle
activity. We also observed that inhibition of glycolysis by 2-de-
oxyglucose inhibited OTC acetylation and concomitantly
increased OTC activity (data not shown). Therefore, OTC
activity may be regulated by cellular energy status.
OTC Lys88 acetylation is also enhanced by amino acids (Fig.
4B). Consistently, OTC activity is inhibited by high amino acid
levels. However, one might expect that high amino acid levels
should increaseOTC activity due to an elevated demand for the
urea cycle. Further studies are needed to clarify the physiolog-
ical regulation of OTC acetylation in response to amino acids.
Important future questions also include how glucose regulates
OTC acetylation.We speculate that glucose may regulate OTC
acetylation by affecting the Sirt family deacetylase. It is possible
that high glucose decreases the cellular concentration of NAD,
which is a cofactor for Sirt, and therefore results in a lower Sirt
activity and increased OTC acetylation. In summary, our study
shows that Lys88 acetylation inhibits OTC enzymatic activity
and that this acetylation is regulated by cellular metabolic sta-
tus and availability of nutrients.
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